Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Zevra Therapeutics Q2 EPS $1.24 Beats $1.13 Estimate, Sales $25.90M Beat $22.49M Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:09pm
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.13 by 10.22 percent. This is a 358.33 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $25.90 million which beat the analyst consensus estimate of $22.49 million by 15.15 percent. This is a 482.15 percent increase over sales of $4.45 million the same period last year.

Posted In: ZVRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist